ChemFeeds Site Navigation:
Journal Selection:
Search:

1) Retraction: Pharmacologic Inactivation of Kinase Suppressor of Ras1 Sensitizes Epidermal Growth Factor Receptor and Oncogenic Ras-Dependent Tumors to Ionizing Radiation Treatment (Molecular Cancer Therapeutics) Monday February 8th 2016


2) ABPP Identifies TBK1 for Small Cell Lung Cancer Therapy (Molecular Cancer Therapeutics) Monday February 8th 2016


3) Choline Kinase in Pancreatic Ductal Adenocarcinoma (Molecular Cancer Therapeutics) Monday February 8th 2016


4) The HLA/MIF Complex as a Surface Target for Ovarian Cancer (Molecular Cancer Therapeutics) Monday February 8th 2016


5) Inhibition of Class I HDACs in Urothelial Carcinoma (Molecular Cancer Therapeutics) Monday February 8th 2016


6) Characterization of EZH2 Inhibitors in Multiple Myeloma (Molecular Cancer Therapeutics) Monday February 8th 2016


7) Nuclear RON in NHEJ DNA Repair (Molecular Cancer Therapeutics) Monday February 8th 2016


8) Inhibition of Endothelial AKT and ERK by 2-DG (Molecular Cancer Therapeutics) Monday February 8th 2016


9) GC1118, with a Distinct EGFR-Binding Epitope and Efficacy (Molecular Cancer Therapeutics) Monday February 8th 2016


10) Synthetic Lethality between CDK and PARP Inhibition (Molecular Cancer Therapeutics) Monday February 8th 2016


11) Optimization of RGD-Containing Peptides (Molecular Cancer Therapeutics) Monday February 8th 2016


12) In Vivo Delivery of Orlistat as Cancer Therapeutic (Molecular Cancer Therapeutics) Monday February 8th 2016


13) pAT2R Gene Therapy Inhibits Lung Cancer via IV/IT Injection (Molecular Cancer Therapeutics) Friday January 8th 2016


14) KillerRed-Based Oncolytic Photodynamic Therapy (Molecular Cancer Therapeutics) Friday January 8th 2016


15) Predictive Value of XIST + 53BP1 in BRCA1-Like Breast Cancer (Molecular Cancer Therapeutics) Friday January 8th 2016


16) Mutated Pathways in Breast Cancer Adjuvant Therapy Patients (Molecular Cancer Therapeutics) Friday January 8th 2016


17) TKI and MEKI for Renal Cell Carcinoma (Molecular Cancer Therapeutics) Friday January 8th 2016


18) TGF{alpha}-EGFR Signaling in Acquired Resistance to Alectinib (Molecular Cancer Therapeutics) Friday January 8th 2016


19) Hydrogen Sulfide Donor Potentiates Radiotherapy (Molecular Cancer Therapeutics) Friday January 8th 2016


20) AKT Inhibition Promotes Cancer Cell Survival (Molecular Cancer Therapeutics) Friday January 8th 2016


21) Rocaglates and eIF4E Phosphorylation (Molecular Cancer Therapeutics) Friday January 8th 2016


22) Paclitaxel Tumor Distribution after Bevacizumab (Molecular Cancer Therapeutics) Friday January 8th 2016


23) Surrobody Simultaneously Activates DR4 and DR5 Receptors (Molecular Cancer Therapeutics) Friday January 8th 2016


24) Perinuclear Localization for {alpha}-Therapy (Molecular Cancer Therapeutics) Friday January 8th 2016


25) Activity of CDK4/6 Inhibitor against Ph+ Leukemia (Molecular Cancer Therapeutics) Friday January 8th 2016


26) Tumor Priming Enhances Nanomedicine Efficacy (Molecular Cancer Therapeutics) Friday January 8th 2016


27) ML264 Inhibits the Growth of Colorectal Cancer (Molecular Cancer Therapeutics) Friday January 8th 2016


28) Targeting Myeloma by Proteasome and XPO1 Inhibitor (Molecular Cancer Therapeutics) Friday January 8th 2016


29) Targeting High-Ploidy Breast Cancer (Molecular Cancer Therapeutics) Friday January 8th 2016


30) Ang-(1-7) Inhibits Proliferation of NPC Cells (Molecular Cancer Therapeutics) Friday January 8th 2016


31) A Top1 Inhibitor Selectively Toxic for Certain NSCLC Cells (Molecular Cancer Therapeutics) Friday January 8th 2016


32) DT01 in Preclinical Models of Colorectal Cancer Liver Metastasis (Molecular Cancer Therapeutics) Friday January 8th 2016


33) Fragment-Based Drug Design of HGF/SF-Met Antagonists (Molecular Cancer Therapeutics) Friday January 8th 2016


34) Acknowledgment to Reviewers (Molecular Cancer Therapeutics) Monday December 7th 2015


35) Lactate Is a Marker of Genotoxic Stress (Molecular Cancer Therapeutics) Monday December 7th 2015


36) VEGFR1 in High-Risk Localized Prostate Cancer (Molecular Cancer Therapeutics) Monday December 7th 2015


37) BRAF Immunohistochemistry in Colorectal Carcinoma (Molecular Cancer Therapeutics) Monday December 7th 2015


38) Severely Impaired and Dysregulated Activities of CYPs in HCC (Molecular Cancer Therapeutics) Monday December 7th 2015


39) A Methylation Gene Panel Predicts Poor Survival in NPC (Molecular Cancer Therapeutics) Monday December 7th 2015


40) Modulation of Mdm2 in the Context of DNA Damage (Molecular Cancer Therapeutics) Monday December 7th 2015


41) PEDF Alleviates Tamoxifen-Induced Endometrial Hyperplasia (Molecular Cancer Therapeutics) Monday December 7th 2015


42) ERK Signal Suppression and Sensitivity to FGFR Inhibitor (Molecular Cancer Therapeutics) Monday December 7th 2015


43) Synergistic Apoptosis by PARP Inhibitors and Temozolomide (Molecular Cancer Therapeutics) Monday December 7th 2015


44) TORC2 Deregulation in HER2-Amplified Cancers (Molecular Cancer Therapeutics) Monday December 7th 2015


45) Systemic PSMA-Targeted IR Sensitization (Molecular Cancer Therapeutics) Monday December 7th 2015


46) Reduced Immunogenicity in an Immunotoxin-Targeting Mesothelin (Molecular Cancer Therapeutics) Monday December 7th 2015


47) High-Dose FOLFIRI plus Bevacizumab in the Treatment of MCRC (Molecular Cancer Therapeutics) Monday December 7th 2015


48) Selumetinib Prevents Lung Metastasis in TNBC (Molecular Cancer Therapeutics) Monday December 7th 2015


49) The Novel IGF1R/INSR Inhibitor BI 885578 (Molecular Cancer Therapeutics) Monday December 7th 2015


50) Aurora A Inhibitor Targets Cervical Cancer (Molecular Cancer Therapeutics) Monday December 7th 2015


51) ABC294640 and Prostate Cancer (Molecular Cancer Therapeutics) Monday December 7th 2015


52) BBB Limits Efficacy of Rucaparib in GBM (Molecular Cancer Therapeutics) Monday December 7th 2015


53) Silibinin Preferentially Radiosensitizes Prostate Cancer (Molecular Cancer Therapeutics) Monday December 7th 2015


54) Inhibition of NK1R Compromises Canonical Wnt (Molecular Cancer Therapeutics) Monday December 7th 2015


55) Synergy between Pan-RAF and MEK Inhibition (Molecular Cancer Therapeutics) Monday December 7th 2015


56) Aurora A and B Kinase Inhibition in Triple-Negative Breast Cancer (Molecular Cancer Therapeutics) Monday December 7th 2015


57) Metronomic Nab-Paclitaxel and Topotecan Inhibit Angiogenesis (Molecular Cancer Therapeutics) Monday December 7th 2015


58) Cutaneous Melanoma Invasion in Human 3D Skin Equivalents (Molecular Cancer Therapeutics) Wednesday November 4th 2015


59) Nasopharyngeal Carcinoma Radioresistance and miR-203 (Molecular Cancer Therapeutics) Wednesday November 4th 2015


60) Seribantumab Delays Resistance, Restores Sensitivity to Aromatase Inhibitors (Molecular Cancer Therapeutics) Wednesday November 4th 2015


61) MET Expression and MET Amplification in Gastric Cancer (Molecular Cancer Therapeutics) Wednesday November 4th 2015


62) Strong Activation of CEBPD by HMDB and 5-AzadC Inhibits HCC (Molecular Cancer Therapeutics) Wednesday November 4th 2015


63) AZD4547 Can Overcome Resistance to MET Inhibitor (Molecular Cancer Therapeutics) Wednesday November 4th 2015


64) Noninternalizing Antibody-Drug Con{#x0237}ugates (Molecular Cancer Therapeutics) Wednesday November 4th 2015


65) Anti-KIT Domain 5 Inhibitory Antibodies (Molecular Cancer Therapeutics) Wednesday November 4th 2015


66) ASC-J9 with BCG Therapy to Better Suppress Bladder Cancer (Molecular Cancer Therapeutics) Wednesday November 4th 2015


67) CP110 Phosphorylation, Stability, and CDK2 Inhibitor Response (Molecular Cancer Therapeutics) Wednesday November 4th 2015


68) Phase I Trial of Birinapant (Molecular Cancer Therapeutics) Wednesday November 4th 2015


69) PARP Inhibition in Pediatric DIPG and HGA (Molecular Cancer Therapeutics) Wednesday November 4th 2015


70) Single-Molecule Top1 Inhibitor Assay (Molecular Cancer Therapeutics) Wednesday November 4th 2015


71) Therapeutic Efficacy of EMICORON against Colon Cancer Xenografts (Molecular Cancer Therapeutics) Wednesday November 4th 2015


72) Generation of Selective Anti-BMP VHHs (Molecular Cancer Therapeutics) Wednesday November 4th 2015


73) Dual HER2/PIK3CA Blockade in USC (Molecular Cancer Therapeutics) Wednesday November 4th 2015


74) Pharmacology of AZD2014, an mTORC1/2 Inhibitor (Molecular Cancer Therapeutics) Wednesday November 4th 2015


75) Screening MMV Malaria Box to Identify Novel Ezrin Inhibitors (Molecular Cancer Therapeutics) Wednesday November 4th 2015


76) AKT1-PDPK1 Interaction Inhibitor (Molecular Cancer Therapeutics) Wednesday November 4th 2015


77) Preclinical Evaluation of POL5551 in Breast Cancer Models (Molecular Cancer Therapeutics) Wednesday November 4th 2015


78) Effect of the Eg5 Inhibitor LY2523355 in Cancer (Molecular Cancer Therapeutics) Wednesday November 4th 2015


79) Sarcoma Cell Line Screen (Molecular Cancer Therapeutics) Wednesday November 4th 2015


80) Response of AKT1E17K-Mutant Tumors to AKT Inhibitors (Molecular Cancer Therapeutics) Wednesday November 4th 2015


81) ABCB1 Inhibition Overcomes Resistance to MET Inhibitors (Molecular Cancer Therapeutics) Wednesday November 4th 2015


82) HDC-Mediated SN-38 Drug Delivery (Molecular Cancer Therapeutics) Wednesday November 4th 2015


83) Didox Circumvents Tamoxifen Resistance (Molecular Cancer Therapeutics) Wednesday November 4th 2015


84) CTC CK20 and Survivin Expression in mCRC (Molecular Cancer Therapeutics) Monday October 5th 2015


85) A pH-Sensitive Antitumor Peptide Nanoformulation (Molecular Cancer Therapeutics) Monday October 5th 2015


86) NSCLC Mouse Model Driven by DDR2 Mutation (Molecular Cancer Therapeutics) Monday October 5th 2015


87) EGFR Degradation and Cetuximab Efficacy (Molecular Cancer Therapeutics) Monday October 5th 2015


88) Activity of 2-DG in AML (Molecular Cancer Therapeutics) Monday October 5th 2015


89) CD24 Induces Drug Resistance in Endometrial Cancer (Molecular Cancer Therapeutics) Monday October 5th 2015


90) Silencing Egr1 Radioprotects Normal but Not Cancer Cells (Molecular Cancer Therapeutics) Monday October 5th 2015


91) Suppression of Thymidylate Biosynthesis by Oxaliplatin (Molecular Cancer Therapeutics) Monday October 5th 2015


92) HDACi-Mediated Sensitization to PARPi (Molecular Cancer Therapeutics) Monday October 5th 2015


93) miR-124 Regulates the ESX/EGFR Signaling Axis (Molecular Cancer Therapeutics) Monday October 5th 2015


94) Cancer-Specific Apoptosis by Targeting 67LR and SphK1 (Molecular Cancer Therapeutics) Monday October 5th 2015


95) Therapeutic Effects of AZD4547 on Endometrial Cancers (Molecular Cancer Therapeutics) Monday October 5th 2015


96) EpCAM Aptamer-siRNAs for Targeted Breast Cancer Treatment (Molecular Cancer Therapeutics) Monday October 5th 2015


97) Engineering of Dual-Targeting Anti-FGFR2/3 Antibodies (Molecular Cancer Therapeutics) Monday October 5th 2015


98) Targeting c-MYC in Ovarian Cancer (Molecular Cancer Therapeutics) Monday October 5th 2015


View: prev | next


Mitch Andre Garcia's Chem Feeds 2008-present

Some images have been reproduced by permission of The Royal Society of Chemistry. (RSC' RSS Policy)
Other images have been reproduced with permission of the American Chemical Society. (ACS' RSS Policy)
Few images have been reproduced with pending permission of Wiley-VCH. ()